Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 4293
  • Home
  • Print this page
  • Email this page
This article has been cited by
1Predictors of Outcome in Patients with Neovascular Age-Related Macular Degeneration Switched from Ranibizumab to 8-Weekly Aflibercept
Irini Chatziralli,Luke Nicholson,Eleni Vrizidou,Chysoula Koutsiouki,Deepthy Menon,Theodoros N. Sergentanis,Maria Cristina Citu,Robin Hamilton,Praveen J. Patel,Phil Hykin,Sobha Sivaprasad
2Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
Irmela Mantel,Mark C. Gillies,Eric H. Souied
Survey of Ophthalmology.2018;63(5)638
3Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence
Usha Chakravarthy,Vladimir Bezlyak,Alexandros Sagkriotis,Ray Griner,Adrian Skelly,David S. Boyer,Fran Milnes
Ophthalmology Retina.2019;3(1)8
4How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
Theodoros Empeslidis,Matthew Storey,Theodoros Giannopoulos,Vassileios Konidaris,Paris G. Tranos,Evangelia S. Panagiotou,Irini C. Voudouragkaki,Anastasios G. Konstas
Advances in Therapy.2019;36(7)1532

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal